United Therapeutics, Medtronic Stop Efforts to Develop Implantable System for Remodulin

By Dave Sebastian

United Therapeutics Corp. and Medtronic Inc. have agreed to stop further efforts to develop and commercialize the implantable system for Remodulin, or ISR.

United Therapeutics Wednesday said the companies plan to wind down the development program and to support patients already enrolled in clinical studies of the ISR at United Therapeutics' sole expense.

The end of the efforts comes after the evolution of treatment options over the past few years, United Therapeutics said. There weren't penalties associated with the termination of the commercialization agreement, it added.

ISR has been developed in the past 12 years to deliver Remodulin injection for patients with pulmonary arterial hypertension through an implantable system developed by Medtronic. The two companies struck a commercialization agreement for the U.S. in February 2019.

Write to Dave Sebastian at [e-mail]

(END) Dow Jones Newswires

06-23-21 0651ET